Evoke Group has acquired Giant Creative Strategy, adding new geograhy and expertise in its aggressive growth strategy.
Bayer's latest campaign rolls with hometown America to show the company's broad array of products and connections to consumers.
J&J’s Invokana will have to wait longer for the FDA to decide on a key label expansion, but it's still got good news to celebrate.
Ogilvy CommonHealth Worldwide recruited Samantha Dolin, an Evoke and Digitas ex, to head up creative in the region.
Thanks to Mylan’s price cut on generic Copaxone, Teva’s going to have to take the price on its branded product down. And it may be wise to start now.
Pfizer and Astellas’ prostate cancer med Xtandi nabbed broader FDA approval, setting it up for a head-to-head fight with J&J’s Erleada.
BioMarin and Believe Limited are helping 25 high schoolers create the first-ever musical about bleeding disorders.
McCann Health has fired its award-winning chief creative officer, Jeremy Perrott, after an unspecified complaint and investigation.
While support from drugmakers can be helpful for patients, sometimes support from fellow patients can be even more helpful. So Bayer is offering both.
With Johnson & Johnson's diabetes drug Invokana going up against two longtime rivals in China, the company is ramping things up.